Why this study matters
Choroideremia is an inherited retinal disease best known for its progressive loss of the choroid and retina, often beginning with night blindness and constricting visual fields. However, other genetic conditions can produce a very similar appearance. A 2026 study in Investigative Ophthalmology & Visual Science followed people with a specific variant in the RHO gene—c.647T>A, p.(Met216Lys)—that can closely mimic choroideremia.
This distinction matters to patients and families because an accurate molecular diagnosis helps explain inheritance within a family, informs genetic counseling, and guides consideration of research studies and future gene-specific treatments. Although RHO variants are a major cause of autosomal dominant retinitis pigmentosa (RP), this particular variant appears to produce an unusual pattern of chorioretinal degeneration rather than the more typical RP picture.
A rare phenotype studied across four centers
Researchers assembled data from four specialist centers in France, the United Kingdom, and the United States. The study included 17 people from eight unrelated families, including 11 women. Their ages at first examination ranged from 13 to 68 years, with a median age of 45 years.
Importantly, 13 participants had follow-up information spanning a median of more than 13 years (159 months), with the longest follow-up approaching 24 years. This long-term view allowed the investigators to document how the condition changes over time rather than relying on a single clinic visit.
Night-vision difficulty was the most common first symptom, reported by 71% of participants. Despite this, central visual acuity—the vision used for reading and recognizing faces—was relatively well preserved at the initial assessment for many individuals. This combination of early night-vision problems with retained central acuity can be seen in several inherited retinal diseases, making detailed imaging and genetic testing particularly important.
A pattern that resembles choroideremia—but has important clues
Visual-field testing revealed rounded blind spots in the mid-peripheral retina, described as pericentral scotomas. Over time, these areas enlarged and merged together. Notably, the far retinal periphery remained relatively spared, at least during the periods observed.
Fundus autofluorescence imaging, which captures signals related to the health of the retinal pigment epithelium, showed age-related differences. Younger participants tended to have a widespread granular pattern. In older participants, the changes evolved into sharply defined patches where autofluorescence was lost, indicating areas of more advanced retinal damage. Serial imaging in seven people confirmed that these patches enlarged and coalesced over time.
This patchy, expanding loss can look strikingly similar to choroideremia. Yet color photographs showed features that may help distinguish this RHO-associated condition: optic disc color was preserved and retinal blood vessels had normal caliber. In many forms of advanced RP, optic disc pallor and narrowed retinal vessels are more prominent.
Optical coherence tomography (OCT), a high-resolution cross-sectional retinal scan, added further detail. The researchers observed outer retinal tubulations—reorganized structures that can form in regions of photoreceptor loss—a thin choroid, and progressive loss of the ellipsoid zone. The ellipsoid zone is an OCT feature associated with photoreceptor integrity. Its width declined at a median rate of 176 micrometers per year in the study, providing one potential measure of disease progression.
What the findings mean for diagnosis and treatment research
The study reinforces that a choroideremia-like retinal appearance does not, by itself, identify the underlying gene. Choroideremia is classically linked to disease-causing variants in the CHM gene, whereas p.(Met216Lys) affects RHO, a gene encoding rhodopsin, a light-sensitive protein in rod photoreceptors.
For individuals whose clinical findings suggest choroideremia, comprehensive genetic testing can therefore be crucial. Identifying an RHO variant rather than a CHM variant changes the genetic explanation for the disease and may alter which gene-specific research programs are relevant to a family.
The findings also underline the value of natural-history studies in treatment development. Before a therapy can be evaluated effectively, researchers need to understand the pace and pattern of change in the untreated condition. Measures such as the expansion of autofluorescence-loss patches and ellipsoid-zone narrowing could help investigators track progression in future studies of this rare phenotype.
The authors conclude that the biological mechanisms behind p.(Met216Lys)-associated disease may differ from those underlying typical RHO-associated RP. That observation is especially important: therapies designed for one RHO-related disease pattern may not automatically address every variant or phenotype in the same way.
Looking ahead
This international study provides a clearer picture of a rare disorder that sits at the intersection of choroideremia-like degeneration and RHO-associated retinal disease. It highlights how multimodal imaging, long-term follow-up, and genetic testing work together to refine diagnosis.
As inherited retinal disease research advances, defining these distinct phenotypes will be essential for matching patients to the most appropriate studies and for designing treatments that account for the specific gene and disease mechanism involved. For families affected by choroideremia-like retinal degeneration, this research is a reminder that the visible retinal pattern is only part of the story; the genetic cause provides the deeper roadmap.

